Rationale and design of the valsartan heart failure trial: A large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure

Jay N. Cohn(University of Minnesota Medical Center), Gianni Tognoni(Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente), Robert Glazer(Novartis (Switzerland)), Dirk Spormann(Novartis (Switzerland)), Allen Hester(Novartis (Switzerland))
Journal of Cardiac Failure
June 1, 1999
10.1016/s1071-9164(99)90038-6
Cited by 146

Abstract

Related Papers

Effect of Captopril on Mortality and Morbidity in Patients with Left Ventricular Dysfunction after Myocardial Infarction
Marc A. Pfeffer, Eugene Braunwald, Lemuel A. Moyé et al.|New England Journal of Medicine|1992|5.9k
The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure
Milton Packer, Michael R. Bristow, Jay N. Cohn et al.|New England Journal of Medicine|1996|4.7k
A Comparison of Enalapril with Hydralazine–Isosorbide Dinitrate in the Treatment of Chronic Congestive Heart Failure
Jay N. Cohn, Gary R. Johnson, Susan Ziesche et al.|New England Journal of Medicine|1991|2.8k
A Clinical Trial of the Angiotensin-Converting–Enzyme Inhibitor Trandolapril in Patients with Left Ventricular Dysfunction after Myocardial Infarction
Lars Køber, Christian Torp‐Pedersen, Jan E. Carlsen et al.|New England Journal of Medicine|1995|1.8k
Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)
Bertram Pitt, Robert Segal, Felipe A Martinez et al.|The Lancet|1997|1.7k